Skip to main content
. Author manuscript; available in PMC: 2015 Jul 29.
Published in final edited form as: N Engl J Med. 2015 Jan 29;372(5):447–455. doi: 10.1056/NEJMsa1406751

Figure 1.

Figure 1

Projected Average Cost-Effectiveness of Full Implementation of the 2014 Guidelines for Hypertension Treatment in Patients without Cardiovascular Disease, According to Sex, Age, Hypertension Stage, and Status with Respect to Diabetes and Chronic Kidney Disease.

Treatment of each group is compared with the strategy outlined in the previous incremental step in the study model for patients in the same age category. Patients with stage 2 hypertension who do not have cardiovascular disease are compared with patients with cardiovascular disease. CKD denotes chronic kidney disease, and ICER incremental cost-effectiveness ratio.